Although this threshold was later reinforced by large-scale screening studies that contributed to the US Food and Drug Administration’s approval of PSA testing for early PCa detection, it does not account for differences in assay methods, leading to potential misinterpretations and incorrect clinical decisions [7], [8]. The gene discussed is KLK3; the disease is posterior cortical atrophy.